A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera®) For Stage I – II Low Grade Follicular Lymphoma

For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be cured.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG (NHLLOW 5); Princess Margaret Hospital, Toronto

Final Accrual

150

Closing Date of Accrual

July 2012

Trial Chairperson

A/Prof Michael Mac Manus, Peter MacCallum Cancer Centre, VIC

Trial Contact

Bev.McClure@petermac.org

Clinical Trial Registration

Related Post

Geoff Zipper - aka Swamp - on the Kokoda Trail
26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

LATEST NEWS: 26 June 2025 He may be 76

24 June, 2025

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report